Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic study of HP-6050 with multiple daily dosing
jRCT2071260042Phase 1Recruiting
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of HP-6050 in delirium, psychomotor agitation and irritability, sponsored by Hisamitsu Pharmaceutical Co., Inc. Primary endpoints: Pharmacokinetics, Safety and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
HP-6050
03
Conditions
deliriumpsychomotor agitationirritability
Beyond the preview
Go deeper on jRCT2071260042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260042.